SAMHD1 and acute myeloid leukemia: Here, the triphosphate metabolite (ara‐CTP) was shown to exclusively be a substrate of SAMHD1 [14, 144, 145], and accordingly, SAMHD1 could dictate the efficacy of this drug in a variety of preclinical AML models [14, 121, 144, 146].